VB-2011

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVB-2011
Drug Alias NameH-11 scFvNovomab-G2 scFvVB-2011VB2-011H-11
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionDiagnostic imaging enhancersAnti-carcinoma associated antigenImmunostimulants +[4] 
TargetsCarcinoma associated antigen
Therapy Area/IndicationsBreast NeoplasmsMelanomaLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At BirminghamViventia Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Alabama At BirminghamViventia Biotech Inc
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsMelanomaLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank